Looking at the situation in hepatitis C and its potential impact on other conditions from a provider standpoint, Ed Cohen, PharmD, FAPhA, offers up many questions to which there may not be answers just yet.
Looking at the situation in hepatitis C and its potential impact on other conditions from a provider standpoint, Ed Cohen, PharmD, FAPhA, offers up many questions to which there may not be answers just yet.
He explained that if the situation isn’t made sustainable so that all patients can participate there is going to be a lot of confusion from patients about why they were or were not eligible for a drug and how they can access the products.
“It will be very interesting to see how this all plays out,” Dr Cohen said.
HIV, Hepatitis C Testing Rates Remain Dismal Among Injection Drug Users
April 17th 2020Despite being at an increased risk for HIV and hepatitis C, persons who inject drugs (PWID) are tested at dismal rates for both: just 8.6% and 7.7%, respectively, according to data from 2010 to 2017. PWID who live in rural communities are more likely to face barriers to adequate testing and care for both diseases.
Read More
Dr Rebekah Gee Offers an Inside Look at Louisiana's Subscription Payment Model for HCV Drugs
May 7th 2019We speak with Dr Rebekah Gee, secretary of the Louisiana Department of Health about the subscription payment model for hepatitis C virus drugs that the state has entered into with Asegua Therapeutics, a subsidiary of Gilead Sciences.
Listen